Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
Cassava Sciences’ presentation is a ‘fireside chat’ with
|Event details follow:|
Cassava Sciences’ fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors’ section.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years,
Simufilam and SavaDx were both developed in-house.
For more information, please visit https://www.CassavaSciences.com
Source: Cassava Sciences, Inc.